FreeCME

Medical Crossfire®: How Can We Maximize Outcomes With PI3K Inhibitors Across Hematologic Malignancies?

/ Print /
| ShareMore
/ Text Size +
12/15/21 12:00 pm EDT
Virtual Webinar
United States


Dysregulation of phosphatidylinositol 3-kinase (PI3K) activity is a common feature in human cancer cells and essential for B-cell survival. Over the past several years, several PI3K inhibitors have been approved or are under investigation for the treatment of patients with hematologic malignancies, including chronic lymphocytic leukemia (CLL) and B-cell lymphomas. Clinicians will need to evaluate the latest clinical data on the efficacy and safety of this class of agents to understand which of their patients will most likely benefit from this treatment strategy.

 Learning Objectives          

 The learning objectives of this program are:

  • Describe the mechanistic rationale supporting the role of PI3K inhibitors in the management of patients with hematologic malignancies in the relapsed and refractory setting
  • Discuss effective strategies for integrating PI3K inhibitors into current clinical practice based on guideline-based recommendations and emerging data for management of patients with hematologic malignancies
  • Assess potential implications of emerging data as well as planned/ongoing trials evaluating current and investigational PI3K inhibitors in hematologic malignancies
  • Plan individualized strategies to optimize treatment with PI3K inhibitors including early recognition and effective management of treatment-related toxicities in hematologic malignancies

 Date

December 15, 2021
12:00 PM - 2:00 PM Eastern Time
Live Webcast

Target Audience

This activity is directed toward primarily hematologists, medical oncologists, and other oncology healthcare professionals interested in the latest advances in the treatment of patients with hematologic malignancies. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the treatment of patients with hematologic malignancies are also invited to attend.